<DOC>
	<DOCNO>NCT00807222</DOCNO>
	<brief_summary>This study involve research test Vyvanse ( study drug ) affect sleep 24 child age 6 12 year ADHD . Vyvanse approve FDA treatment ADHD child age 6 12 year . The experimental part study determine Vyvanse affect sleep .</brief_summary>
	<brief_title>Effect Vyvanse Sleep Children Aged 6-12 Years With Attention Deficit Hyperactivity Disorder ( ADHD )</brief_title>
	<detailed_description>Treatment psychostimulants associate sleep disturbance , include sleep onset maintenance problem , child ADHD . This analysis evaluate effect lisdexamfetamine dimesylate ( LDX ) sleep child ADHD . This single center , double-blind , placebo-controlled , parallel-group trial enrol child age 6-12 year DSM-IV-TR diagnosis ADHD . The study include screening period , 1-week washout , 3-week open-label LDX dose optimization phase , 4-week double-blind treatment phase subject randomize placebo active LDX treatment 30 , 50 , 70 mg/d . Polysomnograph actigraph measure well assessment subjective sleep parameter perform subject prior treatment reassess treatment either LDX placebo .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<mesh_term>Lisdexamfetamine Dimesylate</mesh_term>
	<criteria>1 . Male female subject 6 12 year age , inclusive 2 . Subject meet DSMIVTR criterion primary diagnosis ADHD 3 . Female subject childbearing potential ( FOCP ) must negative urine pregnancy test 4 . Subject must general good health 5 . Subject 's parent legally authorized guardian provide signature informed consent , documentation assent subject . 6 . Subject parent/caregiver willing able comply test requirement define protocol . 7 . Subject generally function academically ageappropriate level 8 . Subject able swallow capsule . 9 . Subject parent/guardian willing comply entire visit schedule study Sleep Hygiene Instructions 1 . Subject comorbid psychiatric diagnosis contraindicate VyvanseTM treatment would confound efficacy safety assessment . 2 . Subject comorbid illness could interfere participation study . 3 . Subject know nonresponder adequate trial stimulant medication ADHD . 4 . Subject history symptom identify sleep disorder 5 . Subject history seizure last 2 year 6 . Subject significantly overweight obese 7 . Subject clinically significant ECG laboratory abnormality screen baseline . 8 . Subject specific cardiac condition family history cardiac disease 9 . Subject take medication affect blood pressure heart rate ( except current ADHD therapy , ) . 10 . Subject positive urine drug result screening ( except current ADHD therapy , ) . 11 . Subject hypertensive . 12 . Subject documented adverse reaction , allergy , intolerance amphetamine dextroamphetamines . 13 . Subject take exclusionary medication 14 . Subject currently ( history previous 12 month ) drug dependence substance abuse disorder 15 . Subject take another investigational product take part clinical trial within 30 day prior Screening ( Visit 1 ) .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>December 2008</verification_date>
	<keyword>ADHD</keyword>
	<keyword>Vyvanse</keyword>
	<keyword>lisdexamfetamine dimesylate</keyword>
	<keyword>LDX</keyword>
	<keyword>sleep</keyword>
</DOC>